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Controversy exists as to whether and how long 
heparin treatment is necessary after infarct vessel 
recanalixation. To detemdne ths role of heparin, 
pathts -with suMable angiographic features after 
rspedmm therapy were randomly allocated to re- 
ceive a brief infusion of intravenous heparin for 
124 hours (group 1), adjusted to a partial throm- 
bopktinthneof2tbnescontroloraprolonged 
intuclson for 172 hours (group 2), using the same 
titraWon mechanism. Patients were excluded for 
complex intimal dissectkns, large residual filling 
defects, less than Thrombolysis in Myocardial In- 
farction grade 3 flow pattern or >SO% residual ste- 
nosis. Heparln was susWnsd except for disconUnu- 
ation 2 to 4 hours before periaccess sheath remov- 
al, or if significant bhding (12 units blood 
transfusion)-. The primary efldpdnts were 
l-week patency determined by repeat catheterk- 
Won or recufvent is&en& or both, and the inci- 
dence of bleeding complicatSons. Fifty patients were 
rat&mixed, 25 in both groups. Basetine variables 
were similar; 14 group 1 and 15 group 2 patients 
receivedthrombolytktreament; 20 patknts in 
eachgrouPhad coronary a&opkwty. Two docu- 
mented reocchlsions occurred in both groups. 6ig- 
nifkantMaedingcomplications occurredinOof25 
(0%)group1versus6of29(24%)group2pa- 
Went8 (p <0.05). Thus, in low-risk patients after 
m mm, -4 hapafin ~atw 
does not protect against rethrombosis and is asso- 
ciated with a significantly higher rate of bleeding 
eomplleaionr. TheMore, prolonged hepartn thera- 
pyfor>24hoursdoesnotappeartobejustifiedin 
low-risk patients with slumsdulreperturion. 
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T he treatment of patients after successful reperfu- sion therapy in the setting of an acute myocardi- al infarction is unclear. In most of the major tri- 
als evaluating reperfusion therapy,‘-3 the use of intrave- 
nous heparin has been empiric because of previous 
anecdotal reports suggesting that the level of anticoagu- 
lation was inversely related to the frequency of recur- 
rent ischemic events.4,5 There have been no randomized 
studies analyzing whether a prolonged infusion of hepa- 
rin is beneficial in maintaining infarct-related artery 
patency in patients after successful reperfusion therapy. 
As previous studies have noted that a significant risk is 
associated with heparin treatment in patients with un- 
derlying medical problems,6-8 we undertook this pilot 
trial to determine whether the risk of heparin therapy 
outweighed the benefit in a group of patients felt to be 
at low risk of reocclusion after successful reperfusion in 
the setting of acute myocardial infarction. 
METHOD6 
Patient populathmr From February 1987 through 
April 1988, 50 patients were treated with reperfusion 
therapy (Table I) for acute myocardial infarction and 
were prospectively randomized to <24 hours (group 1) 
or 172 hours (group 2) infusion of intravenous heparin. 
To be eligible for randomization, the patients had to 
have a diagnosis of acute myocardial infarction with 
chest pain lasting >20 minutes, unrelieved with sublin- 
gual nitroglycerin and electrocardiographic evidence of 
injury with > 1 mm of ST-segment elevation in 22 con- 
tiguous leads. All patients required emergency cardiac 
catheterization and underwent reperfusion therapy. 
Patients were not eligible for randomization if they 
had an unsatisfactory angiographic result after reperfu- 
sion therapy, which included complex dissections,9 re- 
sidual filling defects, less than Thrombolysis in Myocar- 
dial Infarction (TIMI) grade 3 flow pattern or >50% 
visual estimate of residual stenosis. All patients were 
clinically stable at the time of periaccess sheath remov- 
al, which was 124 hours after acute intervention. Ran- 
domization to either a brief (<24 hours) or prolonged 
(172 hours) infusion of heparin was performed at the 
time of sheath removal. During this same 1Cmonth pe- 
riod a total of 164 patients underwent emergency cardi- 
ac catheterization for acute myocardial infarction. The 
majority (69%) were excluded from the current trial ei- 
ther because of failure to meet prespecified angiograph- 
ic criteria or clinical instability in the first 24 hours. 
Catheterization proee&ue~ Patients underwent car- 
diac catheterization if they met the criteria already de- 
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TABLE I Baseline and Treatment Characteristics 
Group 1 Group 2 
(n = 25) (n = 25) 
No. male (%) 21W) 15 (60) 
Age kfrs) 55f9 54f 10 
Infarct coronary artery 
LAD 10 10 
LC 4 2 
Right 11 13 
Total occlusions 11 11 
Thrombolytic alone 6 4 
IV thrombolytics f PTCA 14 15 
Streptokinase 3 1 
t-PA 6 7 
t-PA and urokinase 5 7 
Percent infarct vessel stenosis 30f13 28f12 
Fibrinogen nadir (mg/dl) 170 142 
There were no significant differences (p <0.05) at baseline for the 2 groups. 
IV = intravenous; LAD = left anterior descending; LC = left circumflex; PTCA = 
percutaneous transluminal coronary angioplasty; t-PA = bssue plasminogen activa- 
tor. 
scribed. If the patients were eligible for one of the 
Thrombolysis and Angioplasty in Acute Myocardial In- 
farction protocols, they received either tissue plasmino- 
gen activator (t-PA), urokinase or a combination of 
both, before emergency catheterization. Other patients 
received intravenous streptokinase or no thrombolytic 
therapy before this initial catheterization. 
Using the percutaneous femoral technique, arterial 
and venous sheaths were inserted. At the time of obtain- 
ing vascular access, 5,000 U of intravenous heparin was 
administered. Initial injections of the coronary arteries 
were reviewed, and if an angioplasty was performed, an 
additional 5,000 U of heparin was administered. The 
patients received heparin boluses of 5,000 U hourly dur- 
ing the catheterization procedure. 
At the conclusion of the procedure, the sheaths were 
secured with sutures to the access site and the patient 
received a heparin infusion to maintain the partial 
thromboplastin time at 2 times control (maximum up to 
2.5 times control). The sheaths were withdrawn 24 
hours after the acute catheterization. The heparin was 
discontinued for 2 to 4 hours before sheath removal. At 
this time, patients were eligible for randomization if 
they did not fulfill the angiographic exclusion criteria 
outlined previously. If the patient was randomized to a 
brief infusion (group 1) the heparin was not continued. 
Patients randomized to a prolonged infusion (group 2) 
were restarted receiving heparin therapy with an initial 
bolus of 3,000 to 5,000 U, followed by 800 to 1,200 U/ 
hour, adjusted to maintain the partial thromboplastin 
time to 2 times control. Patients also received 325 mg of 
aspirin/day, diltiazem 30 to 60 mg 4 times/day and in- 
travenous or oral nitrate therapy. 
Patients had 1Zlead electrocardiograms performed 
after reperfusion therapy and daily for 3 days. Creati- 
nine kinase levels with MB isoenzyme analysis were 
performed every 8 hours for the first 24 hours and as 
clinically indicated during the hospitalization. 
Endpoints evaluated during the study included chest 
pain felt to be ischemic in origin with documented elec- 
trocardiographic changes. Urgent recatheterization 
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was then performed, documenting whether restenosis or 
reocclusion of the infarct-related artery had occurred. 
Reocclusion was defined as TIM1 grade 0 or 1 on re- 
peat cardiac catheterization and the percent residual 
stenosis was determined by caliper method. The amount 
and site of bleeding were also evaluated with serial he- 
matocrits and the number of blood transfusions was re- 
corded. A significant bleeding complication was defined 
as requiring L2 units of packed red blood cells. Patients 
were allowed to cross over to the other treatment group 
if recurrent ischemia or significant bleeding endpoints 
were reached. 
RESULTS 
Patient characte!tistics: The baseline clinical and 
angiographic characteristics of the randomized patients 
were similar for the 2 groups and are listed in Table I. 
The groups of patients randomized to a brief or pro- 
longed infusion of heparin were comparable in age, 
male sex, infarct artery, type of intravenous thrombolyt- 
ic agents used, number of total occlusions and percent 
visual estimate of residual stenosis after reperfusion 
therapy. 
Acute reocelusions: Four patients had documented 
reocclusions on follow-up catheterization and were 
evenly divided between both groups. Three of the 4 pa- 
tients had recurrent symptoms and electrocardiographic 
changes suggestive of ischemia before the follow-up 
heart catheterization, of which only 1 was successfully 
recanalized with angioplasty. Only 40 of the 50 patients 
consented to follow-up catheterization. Of the 10 pa- 
tients in whom follow-up catheterization was not per- 
formed, exercise thallium scintigraphy or exercise radio- 
nuclide ventriculography was performed. There was no 
evidence of recurrent ischemia that would suggest reste- 
nosis in any patient. 
Bleeding complications: There were no patients in 
group 1 who had significant bleeding (defined as the 
need for transfusion of 12 units of packed red blood 
cells). In group 2, 6 patients had significant bleeding, 
requiring discontinuation of heparin. A similar number 
of patients received thrombolytic agents in both groups. 
Of the 6 patients who had bleeding complications, 5 
were women, and 5 had received thrombolytic agents 
before the initial catheterization. One patient received 
both intracoronary and intravenous streptokinase, and 1 
patient received a combination of intravenous urokinase 
and t-PA. The other 3 had received intravenous t-PA. 
Sites of bleeding included the periaccess site, genitouri- 
nary (hematuria) and the gastrointestinal tract. No 
cases of intracerebral hemorrhages were noted. 
DISCUSSION 
The optimal prophylactic medical treatment after 
successful reperfusion therapy to maintain coronary ar- 
tery patency is controversial, because in the previous tri- 
als that have used thrombolytic agents or angioplasty, 
or both, intravenous heparin has been continued for at 
least 72 hours after intervention, and usually until hos- 
pital discharge.1-3 In the studies evaluating primary an- 
gioplasty for the treatment of acute myocardial infarc- 
tion, the incidence of late reocclusion has ranged from 2 
to 17%.i”-I2 Treatment with intravenous thrombolysis 
has resulted in late reocclusions ranging from 5 to 
45%.*J3-I5 Virtually all these patients have been treated 
aggressively with medical therapy including heparin and 
aspirin, and still a significant number of patients have 
documented reocclusion or recurrent ischemic events 
during the initial hospitalization. 
Therefore, we have hypothesized that in those pa- 
tients who have a minimal residual stenosis and who 
have no angiographic evidence of dissection or throm- 
bus, there might not be additional benefit with a pro- 
longed heparin infusion. In this group of patients, the 
use of heparin may be detrimental secondary to the risk 
of hemorrhage. We undertook this pilot trial to evaluate 
heparin’s role in preventing reocclusion as well as the 
incidence of bleeding complications in patients undergo- 
ing successful reperfusion therapy. 
In this randomized pilot study, the prolonged use of 
heparin did not appear to prevent reocclusion, as a simi- 
lar proportion (8%) of patients in both groups had docu- 
mented rethrombosis on follow-up catheterization. All 
patients had received heparin therapy for at least the 
initial 24 hours and the randomization was performed 
after this time. We attempted to eliminate patients who 
may have had subclinical thrombus formation at the 
time of the initial catheterization or who may have had 
recurrent ischemic events within the first 24 hours. It 
has been shown that with elective angioplasty and treat- 
ment with t-PA during acute myocardial infarction, re- 
current ischemic events occur most frequently within 
the first 24 hours.‘J After elective angioplasty, full 
anticoagulation for 24 hours was found to be beneficial 
in patients both with and without angiographically visi- 
ble thrombus present. I6 Although an angiogram may 
not demonstrate filling defects to be present, a residual 
thrombus was likely present. Therefore, in the control 
group, 24-hour heparin therapy was instituted. The re- 
sults of our pilot study suggest that beyond this time 
interval, heparin does not appear to be of any added 
benefit in a group of patients who were at low risk of 
reocclusion by clinical and angiographic criteria. 
A significant number of patients had bleeding com- 
plications in the group treated with prolonged heparin 
therapy. Greater than 20% of our patients who were 
treated with 172 hours of heparin required transfusion 
of 12 units of packed red blood cells and discontinua- 
tion of anticoagulation. Of the 6 patients with signifi- 
cant bleeding difficulties, 5 were women and 5 had re- 
ceived thrombolytic agents before the initial catheter- 
ization. All of the blood loss was confined to periac- 
cess site bleeding or gastrointestinal or genitourinary 
sources. Similarly, the TIM1 trialI reported a >15% 
incidence of bleeding events in both the patients treated 
with t-PA or streptokinase. All their patients had a pre- 
treatment catheterization as well as subsequent pro- 
longed intravenous heparin therapy. In the European 
Cooperative Study,3 in which patients were treated with 
t-PA, heparin, aspirin and long-term coumadin therapy, 
there was a 23% incidence of significant bleeding com- 
plications in those treated without early cardiac cathe- 
terization, and a 41% incidence of bleeding in those un- 
dergoing invasive evaluation. 
In our study, a similar number of patients in both 
groups received thrombolytic therapy. Therefore, it is of 
interest that only the group of patients treated with pro- 
longed heparin therapy had significant blood loss re- 
corded. Larger randomized studies are now being per- 
formed that will evaluate the use of prolonged heparin 
therapy in maintaining infarct artery patency in pa- 
tients undergoing thrombolytic therapy alone. Both 
the Third International Study of Infarct Survival and 
Gruppo Italian0 per lo Studio della Supravivenza 
Nell’Infarto Miocardioco trials are evaluating the use of 
high-dose subcutaneous heparin (12,500 U twice daily) 
in patients treated with intravenous streptokinase or t- 
PA and its effect on the in-hospital and long-term out- 
comes. If shown to be effective for reducing reinfarc- 
tion, the use of subcutaneous heparin, as compared to 
the intravenous route, may reduce the risk of significant 
bleeding noted in the current and previous studies.1,2 
The recent Thrombolysis and Angioplasty in Acute 
Myocardial Infarction trial has demonstrated the lack 
of need for intravenous heparin bolus at the initiation of 
t-PA, and the avoidance of early heparin may also be 
effective in reducing hemorrhagic risk. l 7 
A major limitation of our study is the number of 
patients. We did not attempt to detect a significant re- 
duction in the rate of reocclusion with prolonged hepa- 
rin therapy because the number of patients required to 
do this was beyond the scope of our study. To detect a 
50% reduction in reocclusion with a 90% power, an (Y 
error of 0.05 and a p error of 0.10 would require 1,100 
patients. Therefore, larger randomized control studies 
are needed to verify whether prolonged heparin therapy 
reduces the rate of reocclusion and would justify the 
significant bleeding risk determined in our study. The 
other limitations were that only 80% of our patients had 
a repeat coronary angiographic study at the time of hos- 
pital discharge, and we focused on a low-risk subgroup, 
as identified by clinical and angiographic criteria. Silent 
reocclusions may have occurred in the other 10 patients. 
Exercise tomographic thallium scintigraphy as well as 
exercise multigated blood pool images were performed 
in all these patients and no evidence of ischemia was 
demonstrated. This does not, however, rule out silent 
reocclusions with adequate collaterals. Two of these 10 
patients developed recurrent symptoms of angina pecto- 
ris within 6 months, and had evidence of periinfarct 
ischemia on repeat thallium testing. Repeat cardiac 
catheterization demonstrated restenosis but not reocclu- 
sion in both these patients and repeat angioplasty was 
performed with resolution of the symptoms. 
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